Literature DB >> 9700637

Identification of an immunodominant sequential epitope in glycoprotein G of herpes simplex virus type 2 that is useful for serotype-specific diagnosis.

H S Marsden1, K MacAulay, J Murray, I W Smith.   

Abstract

A series of 67 oligopeptides that spanned the open reading frame of herpes simplex virus type 2 (HSV-2) glycoprotein G (gG2) were synthesized and tested for reactivity with 173 serum specimens collected from 117 individuals. The oligopeptides were made as multiple antigenic peptides consisting of four copies of a unique sequence attached to a branched lysine core and separated from the core by four glycine residues. The sera included HSV antibody-negative samples as well as sera from individuals from whom HSV had been isolated. Isolated viruses were typed by indirect fluorescence using a panel of type-specific monoclonal antibodies. One peptide, corresponding to residues 561 to 578 of gG2, did not react with any sera lacking HSV-specific antibodies of with sera from HSV-1-infected individuals, but did react with sera from HSV-2-infected individuals. For sera taken seven or more days after initialclinical lesions, the detection rate of the peptide was 92% (47/51), comparable with the 98% (50/51) of truncated glycoprotein D, a sensitive type-common reagent. We conclude that this peptide, of structure (PEEFEGAGDGEPPEDDDSG4)K3A, is an immunodominant type-specific epitope for human antibodies and should be useful for type-specific serodiagnosis of HSV-2. Surprisingly, the epitope lies within one of the most conserved regions of gG1 and gG2. The test can distinguish an initial HSV-2 infection in the presence of a preexisting HSV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700637     DOI: 10.1002/(sici)1096-9071(199809)56:1<79::aid-jmv13>3.0.co;2-r

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania.

Authors:  Mabula Joseph Kasubi; Arvid Nilsen; Howard S Marsden; Tomas Bergström; Nina Langeland; Lars Haarr
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Conservation of type-specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates.

Authors:  J A Liljeqvist; B Svennerholm; T Bergström
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 4.  Diagnostics for herpes simplex virus: is PCR the new gold standard?

Authors:  Lara B Strick; Anna Wald
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential.

Authors:  Tao Liu; Ji Feng Liu; Hua Yu; Guo Jing Si; Jun Hu; Jun Li
Journal:  Singapore Med J       Date:  2015-06       Impact factor: 1.858

6.  Prevalence of herpes simplex type 2 and syphilis serology among young adults in a rural Gambian community.

Authors:  M Shaw; M van der Sande; B West; K Paine; S Ceesay; R Bailey; G Walraven; L Morison; K McAdam
Journal:  Sex Transm Infect       Date:  2001-10       Impact factor: 3.519

Review 7.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Use of baculovirus-expressed glycoprotein H in an enzyme-linked immunosorbent assay developed to assess exposure to chelonid fibropapillomatosis-associated herpesvirus and its relationship to the prevalence of fibropapillomatosis in sea turtles.

Authors:  Lawrence H Herbst; Shefali Lemaire; Ada R Ene; David J Heslin; Llewellyn M Ehrhart; Dean A Bagley; Paul A Klein; Jack Lenz
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

9.  Use of a fragment of glycoprotein G-2 produced in the baculovirus expression system for detecting herpes simplex virus type 2-specific antibodies.

Authors:  Minako Ikoma; Jan-Ake Liljeqvist; Jan Groen; Koen L Glazenburg; T Hauw The; Sytske Welling-Wester
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

10.  Comparative performance of a novel herpes simplex virus type 2-specific enzyme-linked immunosorbent assay using a targeted chain oligopeptide, peptide 55.

Authors:  A M Al-Sulaiman; P J Vallely; P E Klapper
Journal:  Clin Vaccine Immunol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.